Semiconductor Capital Equipment: Weekly: Earnings Week 4 (CAMT, NVMI, AMAT)

核心结论

SPE earnings season has been unforgiving: only blowout prints (ASMI, MKSI) have triggered positive T+1 reactions. All three companies reporting this week (CAMT, NVMI, AMAT) are likely to beat and raise guidance, but the market may not reward "good" prints. Camtek (EW, PT $161) benefits from China advanced-packaging upside. Nova (EW, PT $453) faces a structural PC headwind that limits outgrowth to single digits. Applied Materials (OW, PT $454) will likely deliver a solid guide (JulQ revenue $8.4bn+, CY26 semi systems growth 25%+), but buy-side feedback suggests it falls short of "blowout" territory. We see modest upside for AMAT, but caution that the setup is priced.

Camtek: China Packaging Tailwind, Lead Times Create Upside

Conclusion: Camtek will raise its CY2026 growth outlook into a high-teens shipment growth range, with upside risk from shorter lead times. The China advanced-packaging theme is real and accelerating.

Evidence: Intra-quarter commentary pointed to incremental strength from China. SEMICON China takeaways from our Greater China semis team confirmed packaging demand strength. ASMPT reported a strong bookings beat. Our preliminary forecast is high-teens shipment growth for CY2026, below our WFE forecast of 23%.

Investment implication: High-teens growth is still below WFE, but Camtek’s shorter lead times mean demand can ramp faster if orders accelerate. The key debate is magnitude of the raise. At ~31x CY27 EPS of $4.89 (6-turn premium to cycle average), the stock already prices in solid growth. We remain Equal-weight, waiting for confirmation of a bull-case EPS of $5.50+ to turn more positive.

Nova: PC Drag Limits Outperformance; Raise Likely but Not Decisive

Conclusion: The process control segment will undergrow WFE in 2026, and Nova’s bull case is single-digit outgrowth rather than the 26ppt/18ppt beats of 2024/2025. Management will likely raise its WFE view, but the path to outperformance is unclear.

Evidence: PC undergrowth relative to WFE is consensus, with debate only on magnitude. At the DecQ report, Nova benchmarked WFE at low double digits; we expect a revision to low 20s. Nova’s execution over two years gives benefit of the doubt, but the setup for 2026 is structurally weaker.

Investment implication: Even if Nova guides to WFE growth (low 20s), re-earning an outgrowth premium will require clear differentiation. We await the print before updating numbers. Stock trades at ~35x CY27 EPS of $12.56 (10% premium to KLA), above its through-cycle average. Equal-weight.

Applied Materials: Good but Not Blowout – Upside Capped Near Term

Conclusion: AMAT will guide JulQ revenue above $8.4bn (Street $8.1bn) and raise CY26 semi systems growth from 20%+ to 25%+. This is "good" but unlikely to provoke a strong rally.

Evidence: Our May 4 preview was positive, but buy-side feedback has tempered the view. SPE earnings pattern shows only blowout prints (ASMI, MKSI) get rewarded. AMAT’s expected results are solid but not exceptional: revenue guide $8.4bn+ vs MSe $8.5bn (slightly below internal estimate), system growth 25%+ vs 20%+.

Investment implication: AMAT is a Top Pick (OW) with $454 target (~28x CY27 EPS of $16.21). The structural DRAM exposure (31% mix vs LAM 20%, KLA 28%) and derisked China/ICAPS story support a positive long-term view. Near term, however, we see limited catalyst for multiple expansion unless the print is meaningfully above our already above-consensus estimates.

Key Divergences and Risks

• SPE earnings market: Only blowout prints (data points: ASMI, MKSI) have rallied. "Good" prints (like what we expect from all three) have been range-bound or sold off. The risk is that upside surprises are insufficient to move stocks.
• China export restrictions: Additional tightening could hit CAMT’s China exposure (30-40% revenue) and AMAT’s China/ICAPS business (20-30%). While we see this as derisked, any escalation is a downside lever.
• PC undergrowth: If WFE weakens more than consensus, Nova’s single-digit outgrowth could become in-line or worse. Consensus is already pricing a premium.
• AMAT competitive pressure: Market share loss vs KLA and LAM in etch/deposition remains a longer-term risk, especially in China.

Valuation and Trading Implications

Near-term trading: We prefer to wait for prints to confirm outgrowth potential before adding positions. AMAT offers the best risk/reward on a 12-month view, but we would look for entry after earnings.